{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:06:50Z","timestamp":1793236010195,"version":"4.5.0"},"reference-count":79,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:sec id=\"ab-jrv240015-1\"><jats:title>Importance<\/jats:title><jats:p>Direct oral anticoagulants (DOACs), comprising apixaban, rivaroxaban, edoxaban, and dabigatran, are commonly used medications to treat patients with atrial fibrillation and venous thromboembolism. Decisions about how to manage DOACs in patients undergoing a surgical or nonsurgical procedure are important to decrease the risks of bleeding and thromboembolism.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jrv240015-2\"><jats:title>Observations<\/jats:title><jats:p>For elective surgical or nonsurgical procedures, a standardized approach to perioperative DOAC management involves classifying the risk of procedure-related bleeding as minimal (eg, minor dental or skin procedures), low to moderate (eg, cholecystectomy, inguinal hernia repair), or high risk (eg, major cancer or joint replacement procedures). For patients undergoing minimal bleeding risk procedures, DOACs may be continued, or if there is concern about excessive bleeding, DOACs may be discontinued on the day of the procedure. Patients undergoing a low to moderate bleeding risk procedure should typically discontinue DOACs 1 day before the operation and restart DOACs 1 day after. Patients undergoing a high bleeding risk procedure should stop DOACs 2 days prior to the operation and restart DOACs 2 days after. With this perioperative DOAC management strategy, rates of thromboembolism (0.2%-0.4%) and major bleeding (1%-2%) are low and delays or cancellations of surgical and nonsurgical procedures are infrequent. Patients taking DOACs who need emergent (&amp;amp;lt;6 hours after presentation) or urgent surgical procedures (6-24 hours after presentation) experience bleeding rates up to 23% and thromboembolism as high as 11%. Laboratory testing to measure preoperative DOAC levels may be useful to determine whether patients should receive a DOAC reversal agent (eg, prothrombin complex concentrates, idarucizumab, or andexanet-\u03b1) prior to an emergent or urgent procedure.<\/jats:p><\/jats:sec><jats:sec id=\"ab-jrv240015-3\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>When patients who are taking a DOAC require an elective surgical or nonsurgical procedure, standardized management protocols can be applied that do not require testing DOAC levels or heparin bridging. When patients taking a DOAC require an emergent, urgent, or semiurgent surgical procedure, anticoagulant reversal agents may be appropriate when DOAC levels are elevated or not available.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2024.12708","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:01:02Z","timestamp":1723474862000},"page":"825","source":"Crossref","is-referenced-by-count":111,"title":["Perioperative Management of Patients Taking Direct Oral Anticoagulants"],"prefix":"10.1001","volume":"332","author":[{"given":"James D.","family":"Douketis","sequence":"first","affiliation":[{"name":"Department of Medicine, St. Joseph\u2019s Healthcare Hamilton, and McMaster University, Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Anticoagulation and Clinical Thrombosis Service, Northwell Health at Lenox Hill Hospital, New York, New York"},{"name":"The Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"},{"name":"Institute of Health System Science at the Feinstein Institutes for Medical Research, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"jrv240015r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37288","article-title":"Clinician trends in prescribing direct oral anticoagulants for US Medicare beneficiaries.","volume":"4","author":"Wheelock","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"7","key":"jrv240015r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.1693","article-title":"National trends in use of and spending on oral anticoagulants among US Medicare beneficiaries from 2011 to 2019.","volume":"2","author":"Troy","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"6","key":"jrv240015r3","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report.","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"1","key":"jrv240015r4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1055\/s-0041-1739411","article-title":"2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary.","volume":"122","author":"Chao","year":"2022","journal-title":"Thromb Haemost"},{"issue":"10264","key":"jrv240015r5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues.","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"jrv240015r6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jth.13305","article-title":"Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery.","volume":"14","author":"Spyropoulos","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"jrv240015r7","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline.","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"issue":"12","key":"jrv240015r8","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/j.amjcard.2019.02.060","article-title":"Meta-analysis of direct-acting oral anticoagulants compared with warfarin in patients &gt;75 years of age.","volume":"123","author":"Malik","year":"2019","journal-title":"Am J Cardiol"},{"issue":"4","key":"jrv240015r9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071907","article-title":"Oral anticoagulant switching in patients with atrial fibrillation: a scoping review.","volume":"13","author":"Adelakun","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"jrv240015r10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/bjs.10643","article-title":"Population-based incidence rate of inpatient and outpatient surgical procedures in a high-income country.","volume":"105","author":"Omling","year":"2018","journal-title":"Br J Surg"},{"issue":"2 Suppl","key":"jrv240015r11","doi-asserted-by":"publisher","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"4","key":"jrv240015r12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 update by the ESC Working Group on Thrombosis.","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"jrv240015r13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/EJA.0000000000001600","article-title":"Regional anaesthesia in patients on antithrombotic drugs: joint ESAIC\/ESRA guidelines.","volume":"39","author":"Kietaibl","year":"2022","journal-title":"Eur J Anaesthesiol"},{"issue":"3","key":"jrv240015r14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/AAP.0000000000000763","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition).","volume":"43","author":"Horlocker","year":"2018","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"jrv240015r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S0392-9590.23.05177-5","article-title":"Prevention and management of venous thromboembolism. International consensus statement. Guidelines according to scientific evidence.","volume":"43","author":"Nicolaides","year":"2024","journal-title":"Int Angiol"},{"issue":"31","key":"jrv240015r16","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.2174\/138161210793563338","article-title":"Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.","volume":"16","author":"Douketis","year":"2010","journal-title":"Curr Pharm Des"},{"issue":"3","key":"jrv240015r17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2023.10.038","article-title":"When direct oral anticoagulants should not be standard treatment: JACC state-of-the-art review.","volume":"83","author":"Bejjani","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"jrv240015r18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4140\/TCP.n.2023.86","article-title":"A review of the safety and efficacy of apixaban in patients with severe renal impairment.","volume":"38","author":"Ifeanyi","year":"2023","journal-title":"Sr Care Pharm"},{"key":"jrv240015r19","doi-asserted-by":"publisher","first-page":"E138","DOI":"10.1093\/eurheartj\/suab109","article-title":"Atrial fibrillation in advanced renal failure: are there alternative solutions to warfarin-dicumarol?","volume":"23","author":"Rossini","year":"2021","journal-title":"Eur Heart J Suppl"},{"issue":"6","key":"jrv240015r20","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1111\/bcp.13092","article-title":"Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.","volume":"82","author":"Parasrampuria","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"jrv240015r21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","article-title":"Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice.","volume":"14","author":"Ferri","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"jrv240015r22","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1055\/s-0040-1716512","article-title":"Effect of direct oral anticoagulant, patient, and surgery characteristics on clinical outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation study.","volume":"4","author":"MacDougall","year":"2020","journal-title":"TH Open"},{"issue":"19","key":"jrv240015r23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017316","article-title":"Predictors of bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation study.","volume":"9","author":"Tafur","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"6 Suppl","key":"jrv240015r24","doi-asserted-by":"publisher","first-page":"299S","DOI":"10.1378\/chest.08-0675","article-title":"The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition).","volume":"133","author":"Douketis","year":"2008","journal-title":"Chest"},{"issue":"3","key":"jrv240015r25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jcjq.2019.12.004","article-title":"\u201cReduce the likelihood of patient harm associated with the use of anticoagulant therapy\u201d: commentary from the anticoagulation forum on the updated Joint Commission NPSG.03.05.01 Elements of Performance.","volume":"46","author":"Dager","year":"2020","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"1","key":"jrv240015r26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/21548331.2018.1420346","article-title":"Evaluating the role of clinical pharmacists in pre-procedural anticoagulation management.","volume":"46","author":"Kataruka","year":"2018","journal-title":"Hosp Pract (1995)"},{"issue":"4","key":"jrv240015r27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.amjmed.2018.11.020","article-title":"Periprocedural antithrombotic management from a patient perspective: a qualitative analysis.","volume":"132","author":"Acosta","year":"2019","journal-title":"Am J Med"},{"key":"jrv240015r28","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620925910","article-title":"Implementation of the management of anticoagulation in the periprocedural period app into an electronic health record: a prospective cohort study.","volume":"26","author":"Spyropoulos","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"jrv240015r29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.thromres.2019.08.007","article-title":"Structure and function of a perioperative anticoagulation management clinic.","volume":"182","author":"Spencer","year":"2019","journal-title":"Thromb Res"},{"issue":"3","key":"jrv240015r30","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1055\/a-2098-6782","article-title":"Potential for a virtual care model in the perioperative management of anticoagulant therapy: a 5-year retrospective clinic review.","volume":"7","author":"Douketis","year":"2023","journal-title":"TH Open"},{"issue":"2","key":"jrv240015r31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bpa.2020.05.001","article-title":"Telemedicine for preoperative assessment during a COVID-19 pandemic: recommendations for clinical care.","volume":"34","author":"Mihalj","year":"2020","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"jrv240015r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.10.028","article-title":"Periprocedural management of direct oral anticoagulants in patients with atrial fibrillation and active cancer.","author":"Shaw","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"2","key":"jrv240015r33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/europace\/euy148","article-title":"Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events.","volume":"21","author":"Nakamura","year":"2019","journal-title":"Europace"},{"issue":"19","key":"jrv240015r34","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/eurheartj\/ehy870","article-title":"When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? a multicentre prospective randomized study.","volume":"40","author":"Yu","year":"2019","journal-title":"Eur Heart J"},{"issue":"5","key":"jrv240015r35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jacep.2017.11.005","article-title":"A prospective randomized trial of apixaban dosing during atrial fibrillation ablation: the AEIOU trial.","volume":"4","author":"Reynolds","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"44","key":"jrv240015r36","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1093\/eurheartj\/ehy413","article-title":"Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).","volume":"39","author":"Birnie","year":"2018","journal-title":"Eur Heart J"},{"key":"jrv240015r37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.thromres.2021.04.006","article-title":"Comparison of temporary interruption with continuation of direct oral anticoagulants for low bleeding risk procedures.","volume":"203","author":"Sheikh","year":"2021","journal-title":"Thromb Res"},{"issue":"4","key":"jrv240015r38","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.4317\/jced.60122","article-title":"Systematic review on the effects of the discontinuation of the anticoagulant therapy and the postoperative bleeding, in patients under new oral anticoagulants after dental extraction.","volume":"15","author":"L\u00f3pez-Galindo","year":"2023","journal-title":"J Clin Exp Dent"},{"key":"jrv240015r39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.702057","article-title":"Bleeding outcomes after dental extraction in patients under direct-acting oral anticoagulants vs. vitamin K antagonists: a systematic review and meta-analysis.","volume":"12","author":"Hua","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"jrv240015r40","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s00417-019-04488-8","article-title":"Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs).","volume":"257","author":"Barequet","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1500","key":"jrv240015r41","first-page":"25","article-title":"Anticoagulation and cataract surgery.","volume":"132","author":"Hung","year":"2019","journal-title":"N Z Med J"},{"issue":"1","key":"jrv240015r42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10792-024-02944-x","article-title":"Effect of direct oral anticoagulants on bleeding during and after cataract surgery.","volume":"44","author":"Maytal","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"11","key":"jrv240015r43","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant.","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"31","key":"jrv240015r44","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1093\/eurheartj\/ehx403","article-title":"Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study.","volume":"38","author":"Godier","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"jrv240015r45","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.thromres.2015.08.006","article-title":"Peri-procedural management of dabigatran and rivaroxaban: duration of anticoagulant discontinuation and drug concentrations.","volume":"136","author":"Godier","year":"2015","journal-title":"Thromb Res"},{"issue":"11","key":"jrv240015r46","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1111\/jth.15850","article-title":"Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants.","volume":"20","author":"Lee","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"jrv240015r47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jvs.2015.11.010","article-title":"Bridging anticoagulation in patients with atrial fibrillation.","volume":"374","author":"Douketis","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv240015r48","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1161\/CIRCULATIONAHA.117.031457","article-title":"Periprocedural outcomes of direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation.","volume":"138","author":"Nazha","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"jrv240015r49","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure.","volume":"113","author":"Douketis","year":"2015","journal-title":"Thromb Haemost"},{"issue":"sup1","key":"jrv240015r50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/00325481.2021.1891751","article-title":"Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery.","volume":"133","author":"D\u2019Astous","year":"2021","journal-title":"Postgrad Med"},{"issue":"3","key":"jrv240015r51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007603","article-title":"Use of direct oral anticoagulants in Canadian primary care practice 2010-2015: a cohort study from the Canadian Primary Care Sentinel Surveillance Network.","volume":"7","author":"McAlister","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"jrv240015r52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa.","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"jrv240015r53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/AAP.0000000000000700","article-title":"Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications (second edition): guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain.","volume":"43","author":"Narouze","year":"2018","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"jrv240015r54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/AAP.0b013e3181c15c70","article-title":"Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition).","volume":"35","author":"Horlocker","year":"2010","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"jrv240015r55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0030-4220(93)90401-O","article-title":"Tranexamic acid as a mouthwash in anticoagulant-treated patients undergoing oral surgery. An alternative method to discontinuing anticoagulant therapy.","volume":"75","author":"Borea","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"jrv240015r56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jds.2018.10.001","article-title":"Efficacy of local tranexamic acid treatment for prevention of bleeding after dental procedures: a systematic review and meta-analysis.","volume":"14","author":"Owattanapanich","year":"2019","journal-title":"J Dent Sci"},{"key":"jrv240015r57","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3389\/fphar.2019.00866","article-title":"Bleeding risk in patients using oral anticoagulants undergoing surgical procedures in dentistry: a systematic review and meta-analysis.","volume":"10","author":"de Andrade","year":"2019","journal-title":"Front Pharmacol"},{"issue":"5","key":"jrv240015r58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.14309\/ajg.0000000000002076","article-title":"Periprocedural management of patients with atrial fibrillation receiving a direct oral anticoagulant undergoing a digestive endoscopy.","volume":"118","author":"Hansen-Barkun","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"jrv240015r59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jcag\/gwac010","article-title":"American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period.","volume":"5","author":"Abraham","year":"2022","journal-title":"J Can Assoc Gastroenterol"},{"issue":"1","key":"jrv240015r60","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.mcna.2018.08.003","article-title":"Colonoscopy, polypectomy, and the risk of bleeding.","volume":"103","author":"Feagins","year":"2019","journal-title":"Med Clin North Am"},{"issue":"6","key":"jrv240015r61","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1067\/mge.2000.105773","article-title":"Postpolypectomy lower GI bleeding: descriptive analysis.","volume":"51","author":"Sorbi","year":"2000","journal-title":"Gastrointest Endosc"},{"issue":"11","key":"jrv240015r62","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1111\/j.1538-7836.2007.02729.x","article-title":"Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).","volume":"5","author":"Dunn","year":"2007","journal-title":"J Thromb Haemost"},{"key":"jrv240015r63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.thromres.2016.01.004","article-title":"Urgent surgery or procedures in patients taking dabigatran or warfarin: analysis of perioperative outcomes from the RE-LY trial.","volume":"139","author":"Douketis","year":"2016","journal-title":"Thromb Res"},{"issue":"5","key":"jrv240015r64","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","article-title":"Reversal agents for non-vitamin K antagonist oral anticoagulants.","volume":"15","author":"Levy","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"jrv240015r65","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"jrv240015r66","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis.","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"jrv240015r67","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221110568","article-title":"Costs and healthcare resource utilization associated with idarucizumab or andexanet alfa oral anticoagulant reversal in patients hospitalized with life-threatening bleeds.","volume":"28","author":"Spyropoulos","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"issue":"15","key":"jrv240015r68","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2146\/ajhp180076","article-title":"Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications.","volume":"75","author":"DeAngelo","year":"2018","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"jrv240015r69","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11239-023-02840-8","article-title":"Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.","volume":"56","author":"Keinath","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"19","key":"jrv240015r70","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage.","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"jrv240015r71","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2022.06.005","article-title":"Management of urgent invasive procedures in patients treated with direct oral anticoagulants: an observational registry analysis.","volume":"216","author":"Godon","year":"2022","journal-title":"Thromb Res"},{"issue":"1","key":"jrv240015r72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.","volume":"49","author":"Frontera","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"15","key":"jrv240015r73","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"issue":"4","key":"jrv240015r74","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.annemergmed.2019.09.001","article-title":"Anticoagulant reversal strategies in the emergency department setting: recommendations of a multidisciplinary expert panel.","volume":"76","author":"Baugh","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"6","key":"jrv240015r75","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum.","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"jrv240015r76","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/rth2.12320","article-title":"Management of oral anticoagulants prior to emergency surgery or with major bleeding: a survey of perioperative practices in North America: communication from the Scientific and Standardization Committees on Perioperative and Critical Care Haemostasis and Thrombosis of the International Society on Thrombosis and Haemostasis.","volume":"4","author":"Levy","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"jrv240015r77","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231179684","article-title":"Comparison of the DOAC dipstick test on urine samples with chromogenic substrate methods on plasma samples in outpatients treated with direct oral anticoagulants.","volume":"29","author":"Papageorgiou","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"jrv240015r78","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2023.125593","article-title":"Calibration-free electrochemical sensor to monitor factor-Xa inhibitors at the point-of-care anticoagulation therapy.","volume":"270","author":"Mruthunjaya","year":"2024","journal-title":"Talanta"},{"issue":"19","key":"jrv240015r79","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1039\/D1LC00465D","article-title":"Point of care whole blood microfluidics for detecting and managing thrombotic and bleeding risks.","volume":"21","author":"Diamond","year":"2021","journal-title":"Lab Chip"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2822177\/jama_douketis_2024_rv_240015_1726758059.26488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:00:30Z","timestamp":1726844430000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2822177"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":79,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.12708","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}